OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Discovery is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis	213
Advances in cryo-electron microscopy (cryoEM) for structure-based drug discovery	117
Training recurrent neural networks as generative neural networks for molecular structures: how does it impact drug discovery?	105
Artificial intelligence in early drug discovery enabling precision medicine	86
Identification of the abnormalities in astrocytic functions as potential drug targets for neurodegenerative disease	62
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis	61
Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery	52
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	50
The current progress in the use of boron as a platform for novel antiviral drug design	50
Advances with the discovery and development of novel sigma 1 receptor antagonists for the management of pain	47
The discovery and development of novel treatment strategies for filoviruses	43
The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies	40
Advances in the discovery of drugs that treat pulmonary arterial hypertension	40
The problem of antimalarial resistance and its implications for drug discovery	39
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design	39
Advances in ion channel high throughput screening: where are we in 2023?	38
What is the future of click chemistry in drug discovery and development?	38
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease	37
Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities	33
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer	32
Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics	31
Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure	29
Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins	28
Maximizing the integration of virtual and experimental screening in hit discovery	27
Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer	27

Opportunities and challenges in new HIV therapeutic discovery: what is the next step?	27
What is an ideal antibiotic and what does this mean for future drug discovery and design?	26
Advances in the discovery of novel agents for the treatment of glaucoma	25
An insight into artificial intelligence in drug discovery: an interview with Professor Gisbert Schneider	24
A more specific concept of a pharmacophore to better rationalize drug design, tailor patient therapy, and tackle bacterial resistance to antibiotics	24
Future prospects of accelerating neuroactive drug discovery with high-throughput behavioral phenotyping	24
Current directions in combining simulation-based macromolecular modeling approaches with deep learning	23
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	23
Fluorescent quantum dots enable SARS-CoV-2 antiviral drug discovery and development	21
The discovery and design of novel HIV-1 capsid modulators and future perspectives	21
The latest advances in high content screening in microfluidic devices	21
Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real	21
Lessons learned from phenotypic drug discovery efforts	21
Electrophilic warheads in covalent drug discovery: an overview	20
In silico drug discovery of melatonin receptor ligands with therapeutic potential	20
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence	20
Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies	20
Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery	19
Developing our knowledge of the quinolone scaffold and its value to anticancer drug design	19
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	18
Discovery of CFTR modulators for the treatment of cystic fibrosis	18
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery	18
Advances in the approaches used to repurpose drugs for neuroblastoma	18
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	18
Promiscuity in drug discovery on the verge of the structural revolution: recent advances and future chances	17
Inhibitors and PROTACs of CDK2: challenges and opportunities	17
Efflux in Gram-negative bacteria: what are the latest opportunities for drug discovery?	17
Omega-3 polyunsaturated fatty acid derived lipid mediators: a comprehensive update on their application in anti-cancer drug discovery	16
Discovery of RNA-targeted small molecules through the merging of experimental and computational technologies	16
What is the plausibility that all drugs will be designed by computers by the end of the decade?	16
γ-Secretase: once and future drug target for Alzheimer’s disease	16
An overview of rational design of mRNA-based therapeutics and vaccines	16
The application of WaterMap-guided structure-based virtual screening in novel drug discovery	15
Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds	15
Artificial intelligence for small molecule anticancer drug discovery	15
Unveiling dynamics of nitrogen content and selected nitrogen heterocycles in thrombin inhibitors: a ceteris paribus approach	15
In vitro screening technologies for the discovery and development of novel drugs against Toxoplasma gondii	15
Advances in the use of 3D colorectal cancer models for novel drug discovery	15
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics	14
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease	14
The latest developments in the design and discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV	14
Strategies for targeting RNA with small molecule drugs	14
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma	14
What are the current challenges for machine learning in drug discovery and repurposing?	13
Galaxy for open-source computational drug discovery solutions	13
Novel approaches to glycomimetic design: development of small molecular weight lectin antagonists	13
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia	13
New insights into the discovery of drugs for triple-negative breast cancer metastasis	13
Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design	12
The discovery and development of gefapixant as a novel antitussive therapy	12

New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi , the causative agent of Chagas disease	12
Targeting AGAT gene expression – a drug screening approach for the treatment of GAMT deficiency	12
Nature as a source and inspiration for human monoamine oxidase B (hMAO-B) inhibition: A review of the recent advances in chemical modification of natural compounds	12
Long non-coding RNA-targeting therapeutics: discovery and development update	12
Validation guidelines for drug-target prediction methods	11
Hydroquinine: a potential new avenue in drug discovery for drug-resistant bacteria?	11
Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery	11
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges	11
Ligand efficiency indices for effective drug discovery: a unifying vector formulation	11
Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature	11
Methods in marine natural product drug discovery: what’s new?	11
What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?	11
Advances in nanotechnology-based platforms for survivin-targeted drug discovery	11
Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase	11
The state of the art of fetal hemoglobin-inducing agents	10
Novel anticancer drug discovery efforts targeting glycosylation: the emergence of fluorinated monosaccharides analogs	10
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies	10
Knowledge graphs and their applications in drug discovery	10
Discovery and design of G protein-coupled receptor targeting antibodies	10
Advances in protein kinase drug discovery through targeting gatekeeper mutations	10
How can we optimize the development of drugs for wound healing?	10
Targeting the adrenomedullin-2 receptor for the discovery and development of novel anti-cancer agents	10
Animal models of Huntington’s disease and their applicability to novel drug discovery and development	10
On-demand modular assembly for expedited PROTAC development	9
The SH-SY5Y cell line: a valuable tool for Parkinson’s disease drug discovery	9
Today’s drug discovery and the shadow of the rule of 5	9
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism	9
Current views on in vivo models for breast cancer research and related drug development	9
Have spirocyclic scaffolds been properly utilized in recent drug discovery efforts?	9
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19	9
Library size in virtual screening: is it truly a number’s game?	9
Designing drugs optimized for both blood–brain barrier permeation and intra-cerebral partition	9
Current strategic trends in drug discovery: the present as prologue	9
The emerging potential of interactive virtual reality in drug discovery	9
How do we further enhance 2D fingerprint similarity searching for novel drug discovery?	9